Aquestive Therapeutics annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aquestive Therapeutics EBITDA Growth & History (AQST)
Aquestive Therapeutics's calculated EBITDA was −$70.5M for fiscal 2025.
View full Aquestive Therapeutics company overviewAquestive Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$70.5M | −$40.5M | — |
| 2024 | 2024-12-31 | −$30.1M | −$16.3M | — |
| 2023 | 2023-12-31 | −$13.8M | $25.9M | — |
| 2022 | 2022-12-31 | −$39.7M | −$8.0M | — |
| 2021 | 2021-12-31 | −$31.7M | $7.7M | — |
| 2020 | 2020-12-31 | −$39.5M | $10.3M | — |
| 2019 | 2019-12-31 | −$49.8M | −$4.0M | — |
| 2018 | 2018-12-31 | −$45.7M | −$49.4M | — |
| 2017 | 2017-12-31 | $3.6M | — | — |
Aquestive Therapeutics quarterly ebitda
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$8.1M | $3.1M | — |
| Q1 2026 | 2026-03-31 | −$4.1M | $15.1M | — |
| Q4 2025 | 2025-12-31 | −$28.7M | −$15.3M | — |
| Q3 2025 | 2025-09-30 | −$11.3M | −$3.2M | — |
| Q2 2025 | 2025-06-30 | −$11.2M | −$11.5M | — |
| Q1 2025 | 2025-03-31 | −$19.2M | −$10.5M | — |
| Q4 2024 | 2024-12-31 | −$13.4M | −$10.0M | — |
| Q3 2024 | 2024-09-30 | −$8.1M | −$6.0M | — |
| Q2 2024 | 2024-06-30 | $260,000 | $4.2M | — |
| Q1 2024 | 2024-03-31 | −$8.8M | −$4.5M | — |
| Q4 2023 | 2023-12-31 | −$3.4M | $6.9M | — |
| Q3 2023 | 2023-09-30 | −$2.1M | $6.1M | — |
| Q2 2023 | 2023-06-30 | −$3.9M | $8.2M | — |
| Q1 2023 | 2023-03-31 | −$4.3M | $4.7M | — |
| Q4 2022 | 2022-12-31 | −$10.3M | $622,000 | — |
| Q3 2022 | 2022-09-30 | −$8.3M | −$1.0M | — |
| Q2 2022 | 2022-06-30 | −$12.1M | −$6.3M | — |
| Q1 2022 | 2022-03-31 | −$9.0M | −$1.2M | — |
| Q4 2021 | 2021-12-31 | −$10.9M | $3.6M | — |
| Q3 2021 | 2021-09-30 | −$7.2M | $5.9M | — |
| Q2 2021 | 2021-06-30 | −$5.8M | −$7.0M | — |
| Q1 2021 | 2021-03-31 | −$7.8M | $5.2M | — |
| Q4 2020 | 2020-12-31 | −$14.5M | −$5.3M | — |
| Q3 2020 | 2020-09-30 | −$13.1M | −$2.9M | — |
| Q2 2020 | 2020-06-30 | $1.2M | $19.1M | — |
| Q1 2020 | 2020-03-31 | −$13.0M | −$683,000 | — |
| Q4 2019 | 2019-12-31 | −$9.3M | $2.3M | — |
| Q3 2019 | 2019-09-30 | −$10.3M | −$1.8M | — |
| Q2 2019 | 2019-06-30 | −$17.9M | $14.0M | — |
| Q1 2019 | 2019-03-31 | −$12.3M | −$18.5M | — |
| Q4 2018 | 2018-12-31 | −$11.6M | — | — |
| Q3 2018 | 2018-09-30 | −$8.5M | −$19.8M | — |
| Q2 2018 | 2018-06-30 | −$31.9M | −$28.8M | — |
| Q1 2018 | 2018-03-31 | $6.3M | — | — |
| Q3 2017 | 2017-09-30 | $11.4M | — | — |
| Q2 2017 | 2017-06-30 | −$3.1M | — | — |
Aquestive Therapeutics ebitda trends
Over the last five fiscal years, Aquestive Therapeutics's ebitda decreased from −$39.5M to −$70.5M, a change of −$31.1M. The latest reported quarter, Q2 2026, shows −$8.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aquestive Therapeutics source filings ↗Community posts
Aquestive resubmits Anaphylm application after FDA rejection
Aquestive ($AQST) Therapeutics resubmitted its US new-drug application for Anaphylm, a sublingual film containing dibutepinephrine for severe allergic reactions, including anaphylaxis. The submission responds to the FDA’s earlier complete r ...
